New type of drug can target all disease-causing proteins

New type of drug can target all disease-causing proteins
Proteolysis targeting chimeras (PROTACs). Credit: (c) Nature Chemical Biology (2015) doi:10.1038/nchembio.1858

Current drugs block the actions of only about a quarter of known disease-causing proteins, but Yale University researchers have developed a technology capable of not just inhibiting, but destroying every protein it targets.

The new type of drug, called Proteolysis Targeting Chimeras (PROTACs), also can continue to destroy mutant proteins in mouse tumors, according to a new study published June 10 in the journal Nature Chemical Biology.

"This new drug modality culminates a decade of work in the field by my lab," said Craig Crews, the Lewis B. Cullman Professor of Molecular, Cellular, and Developmental Biology and senior author of the paper, which was done in collaboration with scientists from GlaxoSmithKline and Arvinas, LLC.

Almost all current drugs are small molecules designed to fit into the folds of disease-causing proteins and inhibit their function. High doses are often needed to ensure that is blocked sufficiently to produce therapeutic results, which in turn can produce harmful side effects.

In contrast, PROTACs engage the cells' own degradation machinery to destroy targeted proteins by tagging them for removal and can do so multiple times, meaning it can work at lower doses, the authors say. This suggests this new type of drug has not only the potential to target proteins that are not currently "pharmaceutically vulnerable" but could do so safely, Crews said.

"This is a game-changer for drug development," Crews said.

Explore further

Researchers design a better way to discover drug candidates

More information: "Catalytic in vivo protein knockdown by small-molecule PROTACs" Nature Chemical Biology (2015) DOI: 10.1038/nchembio.1858
Journal information: Nature Chemical Biology

Provided by Yale University
Citation: New type of drug can target all disease-causing proteins (2015, June 11) retrieved 17 August 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors